Daratumumab Maintenance Improves Survival and Depth of Response in Multiple MyelomaRifkin, Robert M.Journal of Oncology Navigation & Survivorship
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
Results from the LYRA trial showed that the combination of daratumumab with cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant ...
Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center Article 作者:Li, Yanchen;Xu, Shuiqing;Chen, Wenming OBJECTIVE: To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM...
Panelists discuss evolving approaches to maintenance therapy in newly diagnosed multiple myeloma, focusing on balancing survival benefits with tolerability. They also review the latest data from the AURIGA trial evaluating daratumumab and lenalidomide maintenance....
Following the promising addition of a monoclonal antibody, the 3-drug regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone should seamlessly become the new standard of care for relapsed/refractory patients with multiple myeloma, according to Antonio Palumbo, MD. Encouraging findings...
Multiple Myeloma February 17th 2025 Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance May 24th 2024 Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting February 15th 2025 Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refracto...
e20005#Background:DARA has been FDA approved for newly diagnosed multiple myeloma (NDMM) in combination with lenalidomide/dexamethasone (Rd), bortezomib/me... A Ciardiello,N Korde,M Hultcrantz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2022年 Benefit with daratumumab maintenance....
(Darzalex) followed by autologous stem cell transplant (ASCT) and daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation and daratumumab/lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma significantly improved progression-free survival...